Correction to: Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study
J Hematol Oncol. 2018 Jan 9;11(1):5.
doi: 10.1186/s13045-017-0545-5.
1 Department of Epidemiology, Harvard T. H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA, 02115, USA.
2 Fudan University Zhongshan Hospital, Shanghai, China.
3 People's Liberation Army Cancer Center, 81st Hospital of People's Liberation Army, Beijing, China.
4 Academy of Military Medical Sciences, 307th Hospital of PLA, Beijing, China.
5 First Affiliated Hospital of Nanchang University, Nanchang, China.
6 Harbin Medical University Cancer Hospital, Harbin, China.
7 Shandong Cancer Hospital, Jinan, China.
8 Gansu Cancer Hospital, Lanzhou, China.
9 First Affiliated Hospital of Anhui Medical University, Hefei, China.
10 Shanghai First People's Hospital, Shanghai, China.
11 XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai, China.
12 First Affiliated Hospital of Zhejiang University, Hangzhou, China.
13 Jilin Provincial Cancer Hospital, Changchun, China.
14 Fudan University Shanghai Cancer Center, Shanghai, China.
15 Nanjing Medical University, Nanjing, China.
16 Department of Epidemiology, Harvard T. H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA, 02115, USA. [email protected].
17 Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, 75 M. Asias Street, Goudi GR, 115 27, Athens, Greece. [email protected].
18 Department of Oncology, Shanghai East Hospital, Tongji University School of Medicine, No. 150 Ji Mo Road, Shanghai, 200120, People's Republic of China. [email protected].